Marie-Paul Kieny from WHO said the phase I trial experiment of two vaccine candidates has already started, and the other 5 kinds of Ebola vaccines will also begin to test in 2015.

WHO estimated that from October 19^th, nearly 10,000 people were infected by Ebola virus in Sierra Leone, Liberia and Guinea, and about half of the infected people died. The real number may be higher since some cases are not recorded. The epidemic is still spreading at present, an effective vaccine will be the key to change the rules of the game.

The two kinds of vaccine which will be increased the output have been carried out experiment on healthy volunteers. One is from the USA National Institute of allergy and infectious diseases and GlaxoSmithKline joint development, a chimpanzee adenovirus vaccine including Ebola protein surface . It is currently under test in American, England and Maryland.

The other one is a rVSV vaccine developed by the Canada public health agency and NewLind gene company. It is currently under test in America, and it’s going to be tested in Europe and Africa. The third candidate vaccine is a combination of the two kinds of vaccines: one developed by the United States Johnson Corporation and the National Institute of allergy and infectious diseases research, another developed by the Danish Biotech Corp Bavarian Nordic production. Its phase I trial will begin in January next year in the United States and Europe.